http://orcid.org/0000-0002-5700-8578
Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Sara Kolehmainen, Tero Ylisaukko-oja, Jari Jokelainen, Mirkka Koivusalo, T. Sakari Jokiranta & Taina Sipponen. (2021) Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting. Scandinavian Journal of Gastroenterology 56:8, pages 906-913.
Read now
Read now
Robert Battat, Parambir S. Dulai, Vipul Jairath & Niels Vande Casteele. (2019) A product review of vedolizumab in inflammatory bowel disease. Human Vaccines & Immunotherapeutics 15:10, pages 2482-2490.
Read now
Read now
Articles from other publishers (20)
T. Kucharzik, A. Dignass, R. Atreya, B. Bokemeyer, P. Esters, K. Herrlinger, K. Kannengiesser, P. Kienle, J. Langhorst, A. Lügering, S. Schreiber, A. Stallmach, J. Stein, A. Sturm, N. Teich & B. Siegmund. (2023) Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009. Zeitschrift für Gastroenterologie 61:08, pages 1046-1134.
Crossref
Crossref
Asaf Levartovsky, Ido Cohen, Chaya Mushka Abitbol, Miri Yavzori, Ella Fudim, Orit Picard, Uri Kopylov, Shomron Ben-Horin & Bella Ungar. (2023) Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?. Biomedicines 11:6, pages 1553.
Crossref
Crossref
Niels Vande Casteele, Lili Yang, Iwona Dobler, Christian Agboton, Teresa McRorie Osborn, Ajit Suri, Dirk Lindner & Glennda M. Smithson. (2023) Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay. Therapeutic Drug Monitoring 45:2, pages 236-244.
Crossref
Crossref
Merve Sivridaş, Rob H. Creemers, Dennis R. Wong, Paul J. Boekema, Tessa E. H. Römkens, Lennard P. L. Gilissen, Adriaan A. van Bodegraven, Floris C. Loeff, Theo Rispens & Luc J. J. Derijks. (2023) Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study. Pharmaceutics 15:3, pages 972.
Crossref
Crossref
Doaa Anbarserry, Mahmoud Mosli, Yousef Qari, Omar Saadah, Rana Bokhary, Ahmed Esmat, Mohammed Alsieni, Ahmed Shaker, Ramu Elango & Sameer Alharthi. (2023) The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease. Scientific Reports 13:1.
Crossref
Crossref
Ulf Helwig, Thomas Helmut Krause, Christian Maaser, Jürgen Büning, Attyla Drabik, Margit Blömacher, Sandra Plachta-Danielzik, Niels Teich, Annette Krummenerl, Andreas Sturm, Matthias Schwab & Stefan Schreiber. (2023) Early MOnitoring of REsponse (MORE) to Golimumab Therapy: Results of a Multicentre, Prospective Observational Trial. Digestive Diseases 41:2, pages 239-249.
Crossref
Crossref
Emily Becker, Mark Dedden, Christine Gall, Maximilian Wiendl, Arif Bülent Ekici, Anja Schulz-Kuhnt, Anna Schweda, Caroline Voskens, Ahmed Hegazy, Francesco Vitali, Raja Atreya, Tanja Martina Müller, Imke Atreya, Markus F Neurath & Sebastian Zundler. (2022)
Residual homing of α4β7-expressing β1
+
PI16
+
regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab
. Gut 71:8, pages 1551-1566.
Crossref
Crossref
Niels Vande Casteele, William J. Sandborn, Brian G. Feagan, Séverine Vermeire, Parambir S. Dulai, Andres Yarur, Xavier Roblin, Shomron Ben‐Horin, Iris Dotan, Mark T. Osterman, Maria Rosario, Teresa McRorie Osborn, Julian Panes, Dirk Lindner & Christian Agboton. (2022)
Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel disease:
ERELATE
Study
. Alimentary Pharmacology & Therapeutics 56:3, pages 463-476.
Crossref
Crossref
William J. Sandborn, Larry C. Mattheakis, Nishit B. Modi, David Pugatch, Brian Bressler, Scott Lee, Raj Bhandari, Bittoo Kanwar, Richard Shames, Geert D’Haens, Stefan Schreiber, Silvio Danese, Brian Feagan, Rish K. Pai, David Y. Liu & Suneel Gupta. (2021) PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. Gastroenterology 161:6, pages 1853-1864.e10.
Crossref
Crossref
Antonello Di Paolo & Giacomo Luci. (2021) Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Frontiers in Pharmacology 11.
Crossref
Crossref
Torsten Kucharzik, Axel U. Dignass, Raja Atreya, Bernd Bokemeyer, Philip Esters, Klaus Herrlinger, Klaus Kannengießer, Peter Kienle, Jost Langhorst, Andreas Lügering, Stefan Schreiber, Andreas Stallmach, Jürgen Stein, Andreas Sturm, Niels Teich & Britta Siegmund. (2020) Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Zeitschrift für Gastroenterologie 58:12, pages e241-e326.
Crossref
Crossref
Dahham Alsoud, Séverine Vermeire & Bram Verstockt. (2020) Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?. Current Opinion in Pharmacology 55, pages 17-30.
Crossref
Crossref
Francesca Penagini, Lucia Cococcioni, Elena Pozzi, Dario Dilillo, Giulia Rendo, Cecilia Mantegazza & Gian Vincenzo Zuccotti. (2020) Biological therapy in pediatric age. Pharmacological Research 161, pages 105120.
Crossref
Crossref
Séverine Vermeire, Milan Lukáš, Fernando Magro, Shashi Adsul, Dirk Lindner, Maria Rosario, Jeannine Roth & Silvio Danese. (2020) Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis. Journal of Crohn's and Colitis 14:8, pages 1066-1073.
Crossref
Crossref
Lieven Pouillon, Séverine Vermeire & Peter Bossuyt. (2019) Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. BMC Medicine 17:1.
Crossref
Crossref
Jimmi Cording, Margit Blömacher, Berit Inga Wiebe, Jost Langhorst, Torsten Kucharzik, Andreas Sturm, Stefan Schreiber & Ulf Helwig. (2019) Monitoring of Vedolizumab Infusion Therapy (MOVE-IT) Response With Fecal Inflammation Markers, Ultrasound, and Trough Serum Level in Patients With Ulcerative Colitis: Protocol for a Multicentric, Prospective, Noninterventional Study. JMIR Research Protocols 8:11, pages e14335.
Crossref
Crossref
Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Barbara Tolusso, Clara Di Mario, Eleonora Albano, Gherardo Tapete, Elisa Gremese, Alfredo Papa, Antonio Gasbarrini, Gian Ludovico Rapaccini & Alessandro Armuzzi. (2019) Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United European Gastroenterology Journal 7:9, pages 1189-1197.
Crossref
Crossref
Jurij Hanžel, Nejc Sever, Ivan Ferkolj, Borut Štabuc, Nataša Smrekar, Tina Kurent, Matic Koželj, Gregor Novak, Griet Compernolle, Sophie Tops, Ann Gils & David Drobne. (2019) Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. United European Gastroenterology Journal 7:6, pages 741-749.
Crossref
Crossref
Mark T. Osterman, Maria Rosario, Karen Lasch, Morris Barocas, Jayson D. Wilbur, Nathanael L. Dirks & Marc R. Gastonguay. (2019) Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Alimentary Pharmacology & Therapeutics 49:4, pages 408-418.
Crossref
Crossref
Gerhard Rogler. (2019) Mechanism of action of vedolizumab: do we really understand it?. Gut 68:1, pages 4-5.
Crossref
Crossref